Atlanticus Announces "Modified Dutch Auction" Tender Offer

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Atlanticus Announces "Modified Dutch Auction" Tender Offer to Purchase up to $100.0 Million Aggregate Principal Amount of Its Outstanding 5.875% Convertible Senior Notes Due 2035 at a Purchase Price of up to $420 per $1,000 Principal Amount of Notes

ATLANTA, GA--(Marketwired - Jun 23, 2014) - Atlanticus Holdings Corporation ( NASDAQ : ATLC ) ("Atlanticus") today announced that it has commenced a "Modified Dutch Auction" cash tender offer (the "Tender Offer") for up to $100.0 million aggregate principal amount of its outstanding 5.875% Convertible Senior Notes due 2035 (the "Notes"). Under the "Modified Dutch Auction" procedure, Atlanticus is offering to purchase the Notes at a price (in multiples of $0.50 per $1,000 principal amount) not greater than $360 or less than $300 per $1,000 principal amount of such Notes. Atlanticus will select the lowest purchase price that will allow it to purchase up to $100.0 million aggregate principal amount of the Notes. If an aggregate of $75.0 million or more in principal amount of the Notes is validly tendered, Atlanticus will pay a purchase price of $420 per $1,000 principal amount of the Notes validly tendered and accepted for purchase, subject to the maximum purchase amount of $100.0 million.

A "Modified Dutch Auction" tender offer allows holders of the Notes to indicate the principal amount of Notes that such holders desire to tender and the price within the indicated price range at which they wish to tender such Notes. Only Notes validly tendered at prices at or below the applicable purchase price selected by us, and not properly withdrawn, will be purchased, subject to proration.

As of June 19, 2014, there were approximately $139.5 million aggregate principal amount of the Notes outstanding.

The Tender Offer is scheduled to expire at 11:59 p.m., New York City time, on July 21, 2014, unless extended by Atlanticus (as such time and date may be extended, the "Expiration Date"). Tenders of Notes must be made on or prior to the Expiration Date and Notes may be withdrawn at any time on or prior to the Expiration Date.

The Tender Offer and Atlanticus' obligation to purchase and pay for the Notes validly tendered and not validly withdrawn is subject to the conditions set forth in the Offer to Purchase (as described below) being satisfied or waived on or prior to the Expiration Date.

Atlanticus will fund the purchase of Notes tendered in the Tender Offer through a new loan obtained solely for the purposes of the Tender Offer. This loan will be secured with all available collateral and will be senior in right of payment to the Notes and any other current or future unsecured obligations of Atlanticus.

U.S. Bank National Association is the paying agent for the Tender Offer and the trustee under the indenture governing the terms of the Notes. For additional information regarding the Tender Offer, contact U.S. Bank at (800) 934-6802 or cts.specfinance@usbank.com .

This press release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell the Notes. The tender offer is being made pursuant to the tender offer documents, including the Offer to Purchase, dated June 23, 2014. Note holders are urged to read the tender offer statement on Schedule TO filed with the Securities and Exchange Commission (the "SEC") on June 23, 2014. The Schedule TO includes as an exhibit the Offer to Purchase. These documents have been filed with the SEC and Note holders may obtain them without charge from the SEC at its website ( www.sec.gov ) or from the paying agent at the contact information listed above.

The Tender Offer is not being made in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction. None of Atlanticus, the paying agent or the trustee for the Notes makes any recommendation in connection with the Tender Offer.

About Atlanticus Atlanticus invests in businesses primarily focused in the financial services industry. Additional information about Atlanticus is available at www.atlanticus.com .

Forward-Looking Statements This press release contains forward-looking statements. Statements regarding future events are based on Atlanticus' current expectations. Actual results may differ materially from those suggested by any forward-looking statement. Forward-looking statements are necessarily subject to associated risks. Information regarding the factors that may impact Atlanticus' performance is included in Atlanticus' reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended March 31, 2014. In providing forward-looking statements, Atlanticus expressly disclaims any obligation to update publicly or otherwise these statements, whether as a result of new information, future events or otherwise.

U.S. Bank (800) 934-6802 cts.specfinance@usbank.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Driven Tech Lands on 2026 CRN AI Innovators List

Updated Category News Views 4

New Milestone for Driven Tech in AI Innovation If there's one thing that's becoming crystal clear in the tech world, it's this: AI isn't just a flashy add-on anymore. Companies are diving deep into AI waters, transforming their business strategies from the ground up. Driven Tech, Inc., is doing just that, and their efforts haven't gone unnoticed—they’ve made it onto...

Continue Reading
Clarivate Taps Global Appetite for AI Research Tools

Updated Category News Views 8

A Growing Global Thirst for AI-Enhanced Research It looks like the folks at Clarivate have struck a chord. Their Web of Science Research Intelligence platform is garnering attention across the globe, embraced by more than 100 institutions spanning 25 countries. When you craft something that taps into a core need, well, people will jump on it—and that's exactly what's...

Continue Reading
PKGD Group's Agave Spirits Surge 56% in 2026 Growth'

Updated Category News Views 1

PKGD Group's Impressive Growth Story Sometimes you read a report and it genuinely knocks the wind out of you—not because it’s unusual, but because it’s rare to see such robust numbers in a market that ain't exactly all sunshine and rainbows. PKGD Group, the brain behind some damn fine agave spirits, decided to take no prisoners this year, reporting a jaw-dropping...

Continue Reading
ELEGOO's M1 Ultra: Bridging Gap in 3D Scanning Tech

Updated Category News Views 3

A Leap in 3D Scanning: Say Hello to M1 Ultra ELEGOO isn't just fiddling with a toy here—this Shenzhen-based juggernaut is rolling out the M1 Ultra on October 29, 2026, and it's causing quite a stir. While the stock market doesn't see immediate tremors from every shiny new gadget, there’s something to say when a company that pulled over $300 million in sales last year...

Continue Reading
Rznomics Advances with EU Orphan Status for RZ-001

Updated Category News Views 3

RZ-001's European Success: A New Frontier Look, when a biopharmaceutical firm's RNA-editing therapy snags an Orphan Medicinal Product Designation from the European Commission, it's not just some clipboard milestone—it's a heavy-hitter move. That's exactly what Rznomics, the South Korean gene therapy player, pulled off with RZ-001. Now, we aren't just seeing paperwork...

Continue Reading
Durabook R12 Tablet: A Rugged Revolution for AI Tasks

Updated Category News Views 7

Edge AI Gets a Rugged Boost with Durabook's R12 In a world teeming with tech gadgets that crumble at the first sign of a challenge, Durabook's R12 Rugged Tablet makes a solid entrance. This ain't your everyday pretty gadget. Think of it as the big, burly bodyguard of tablets, ready to box through harsh environments without dropping a pixel. What’s stirring the pot this...

Continue Reading
When Families Should Consider Life Insurance Plans

Updated Category News Views 0

Let’s talk about why life insurance isn’t just for those walking around with gray hair. K.D. the Insurance Queen from Centennial, Colorado, dishes out the clearest advice on when and why families ought to have it in their arsenal. A New Mindset on Life Insurance Some folks out there think life insurance is something you ponder in your twilight years. But here’s the...

Continue Reading
Hims & Hers Faces Class Action: Investor Implications

Updated Category News Views 6

Serious Scrutiny for Hims & Hers There's trouble in paradise, folks. Hims & Hers Health, Inc. (NYSE: HIMS) just landed in hot water, and it's not the soothing kind. We're talking about allegations of privacy violations and deceptive practices that have sent ripples—or more like waves—across the investor pond. If you're holding shares, you've probably felt the jolt...

Continue Reading
UMC and AP Memory Boost Power with New AI Chips

Updated Category News Views 4

Breaking Ground in Data Center Power Every so often, the tech industry gets a jolt of innovation that turns heads—not just for what it can do today, but for what it promises tomorrow. This time, it's United Microelectronics Corporation (UMC) and AP Memory shaking things up with their collaboration aimed at redefining power delivery for AI and high-performance computing...

Continue Reading
AuraQuantic Leads SPARK Matrix™ in 2026 IPO Ranking

Updated Category News Views 2

Not Just Another Day in Tech When tech outfits make headlines, it's often because of a shiny new gadget or some jarring security breach. Today, it's AuraQuantic getting their well-deserved spotlight, having snagged the leader's spot in the SPARK Matrix™ for Intelligent Process Orchestration (IPO). You might be wondering what makes this accolade worth attention in a...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Atlassian's Recent Options Activity Surge

Updated Category News Views 163

Analyzing Atlassian's Options Activity Recently, significant activity has been noted in the options market for Atlassian (NASDAQ: TEAM), suggesting fluctuating sentiment among investors. With several key trades occurring, it is vital to understand the underlying forces driving these changes. Insights from Options Trading An examination of options history indicates that a...

Continue Reading
Oncolytics Biotech's Strategic Move to Lead Cancer Innovation

Updated Category News Views 176

Oncolytics Biotech's Strategic Move to Lead Cancer Innovation In a time where the global oncology drug market is projected to exceed an astounding $900 billion, interest in cancer-focused biotechnology companies has surged significantly. Analysts highlight the increasing demand for innovative diagnostics and advanced immunotherapies driving this growth. Yet, as these...

Continue Reading
Transformations in Admirals Group AS Leadership and Governance

Updated Category News Views 170

Changes in Leadership at Admirals Group AS Admirals Group AS recently held a significant general meeting where key changes to its management and supervisory boards were decided. Effective from a stated future date, Anton Tikhomirov and Fedor Ragin have been appointed to the supervisory board for a term of five years. This shift marks an exciting new chapter in the...

Continue Reading
Athens Stock Market Reaches New Heights with Gains

Updated Category News Views 175

Athens Stock Market Performance Overview The latest updates reveal that Greece's stock market has closed on a positive note, showcasing notable increases across various sectors. The Athens General Composite Index has gained traction, finishing higher as key market sectors, particularly Construction, Travel, and Banking, experienced substantial growth. Sectorwise...

Continue Reading
Johnson & Johnson's Tremfya Shows Promising Results for Crohn's Disease

Updated Category News Views 227

Introduction to Tremfya and Crohn's Disease Tremfya, a medication developed by Johnson & Johnson, has gained notable attention for its role in treating Crohn's disease. Recently, new results from its Phase 3 GRAVITI study have sparked interest in its potential expanded usage, showing promising outcomes for patients. Exciting Results from the GRAVITI Study The GRAVITI...

Continue Reading